Need an expert perspective on cancer science, policy, or patient care? ASCO experts are knowledgeable on a wide variety of cancer topics. Expert Connect showcases a selection of the experts ASCO has available for media interviews. If you’d like to interview one of the experts below, or you’re uncertain about who you’d like to speak with, please email mediateam@asco.org, and we will do our best to connect you with the appropriate expert.
Disclosures for the experts listed below can be referenced here.

Everett E. Vokes, MD, FASCO
x

Dr. Vokes specializes in head and neck and lung cancers. He is the John E. Ultmann Professor, chair of the Department of Medicine, and physician-in-chief at the University of Chicago Medicine and Biological Sciences. He is the former leader of the Respiratory Committee of the Alliance ( formerly  Cancer and Leukemia Group B ) and serves on the editorial boards of several journals. He is a past chair of the Annual Meeting Education Committee, Annual Meeting Scientific Program Committee, and a member of the Conquer Cancer Development and Fundraising Committee, and the Cancer.Net Editorial Board. He served as an elected member of the ASCO Nominating Committee, and on the Board of Directors from 2009-2012.

View current ASCO disclosure here

Expertise:
Request Interview
Eric P. Winer, MD, FASCO
x

Dr. Winer has been elected to serve as the ASCO President in 2022-2023. He is the chief clinical development officer, senior vice president for medical affairs, chief of the Division of Breast Oncology, and the Thompson Chair in Breast Cancer Research at Dana-Farber Cancer Institute. He is also a professor of medicine at Harvard Medical School. Dr. Winer served on the ASCO Board of Directors from 2011 to 2015, and has served as chair of the ASCO Government Relations Committee, Cancer Communications Committee, and Health Services Research Committee, among numerous volunteer roles. He is the 2017 recipient of ASCO’s Gianni Bonadonna Breast Cancer Award and Lecture.

View current ASCO disclosure here.

Expertise:
Request Interview
Lori J. Pierce, FASTRO, MD, FASCO
x

Dr. Pierce is a radiation oncologist, professor, and Vice Provost for Academic and Faculty Affairs at the University of Michigan. She is also director of the Michigan Radiation Oncology Quality Consortium. A national leader in breast cancer research, Dr. Pierce was previously a Senior Investigator at the National Cancer Institute, National Institutes of Health and in 1992, joined the faculty at the University of Michigan where she has focused her career primarily on the treatment of breast cancer.

An active ASCO member since 1992, Dr. Pierce is a past member of multiple ASCO committees including the Government Relations Committee, Annual Meeting Scientific Program Committee, and the Conquer Cancer Foundation Nominating Committee, and she served as a mentor for the Leadership Development Program from 2015 to 2018. She previously served on the ASCO Board of Directors from 2010 – 2014 and was named a Fellow of ASCO (FASCO) in 2015. 

With over 180 manuscripts and book chapters published, Dr. Pierce has received numerous teaching and leadership awards including the American Association of Women Radiologists' Marie Curie Award and the Hologic, Inc Endowed Women Who Conquer Cancer Mentorship Award. In 2018, she was elected into the National Academy of Medicine. Most recently, Dr. Pierce was selected as the 2019 Woman of the Year by the United Way of Washtenaw County (UWWC) of Michigan.

Dr. Pierce completed her undergraduate degree in biomedical engineering at the University of Pennsylvania and her medical degree at Duke University. She completed her internship at the Thomas Jefferson University Hospital and her residency and chief residency in Radiation Oncology at the University of Pennsylvania.

View current ASCO disclosure here.

Expertise:
Request Interview
Howard A. Burris III, MD, FACP, FASCO
x

Dr. Burris serves as president and chief medical officer of Sarah Cannon, as well as the executive director, drug development for the research institute. He is an associate of Tennessee Oncology, PLLC, where he practices medical oncology.

Dr. Burris' clinical research career has focused on the development of new cancer agents with an emphasis on first in human therapies, having led the trials of many novel antibodies, small molecules, and chemotherapies now FDA approved, including ado-trastuzumab emtansine, everolimus, and gemcitabine. In 1997, he established in Nashville the first community based early phase drug development program, which grew into the Sarah Cannon Research Institute. He has authored over 400 publications and 700 abstracts. Sarah Cannon has now dosed over 350 first in human anticancer therapies and enrolls more than 3000 patients per year into clinical trials.

Dr. Burris served as the elected president of ASCO in 2019-2020. He currently serves as the Chair of the Society's Board and also as the Chair of the Board of ASCO’s Conquer Cancer Foundation. Additionally in 2014, Dr. Burris was selected by his peers as a Giant of Cancer Care for his achievements in drug development.

Dr. Burris completed his undergraduate education at the United States Military Academy at West Point, his medical degree at the University of South Alabama, and his internal medicine residency and oncology fellowship at Brooke Army Medical Center in San Antonio. While in Texas, he also served as the Director of Clinical Research at The Institute for Drug Development of the Cancer Therapy and Research Center and The University of Texas Health Science Center. He attained the rank of lieutenant colonel in the US Army, and among his decorations, he was awarded a Meritorious Service Medal with oak leaf cluster for his service in Operation Joint Endeavor.  

View current ASCO disclosure here.

Expertise:
Request Interview
Clifford A. Hudis, MD, FACP, FASCO
x

Dr. Hudis is the Chief Executive Officer of the American Society of Clinical Oncology (ASCO). He also serves as the Executive Vice Chair of its Conquer Cancer Foundation and Chair of ASCO’s CancerLinQ. Dr. Hudis previously served in a variety of volunteer and leadership roles at ASCO, including as its President during the Society’s 50th anniversary year (2013-14). Before coming to ASCO full-time, he was the Chief of the Breast Medicine Service at Memorial Sloan Kettering Cancer Center (MSKCC) in New York City and Professor of Medicine at the Weill Medical College of Cornell University. As CEO of ASCO, Dr. Hudis is responsible for delivering on the board’s strategic goals through education, research, and support for the delivery of the highest quality of care by the Society’s nearly 45,000 members.

Read Dr. Hudis’ Q&A on ASCO Connection.

View current ASCO disclosure here.

Expertise:
Breast Cancer, Obesity and Cancer
Request Interview
Julie R. Gralow, MD, FACP, FASCO
x

Dr. Gralow is the Chief Medical Officer (CMO) and Executive Vice President of ASCO, and brings to her role deep expertise in patient care, research, education, and global health.

Previously, she was the Jill Bennett Endowed Professor of Breast Cancer at the University of Washington School of Medicine, Professor in the Clinical Research division of the Fred Hutchinson Cancer Research Center, as well as Director of Breast Medical Oncology at the Seattle Cancer Care Alliance.

Dr. Gralow is strongly committed to advancing equity in cancer care. As founder of the Women’s Empowerment Cancer Advocacy Network (WE CAN), she supports patient advocates in low- and middle-resource countries. In addition, she served as an adjunct professor in the University of Washington’s Department of Global Health, as a member of the University of Washington’s Breast Cancer Equity Initiative, as Medical Director for Women’s Cancer-related Population Health at the University of Washington, and as an advisory council member for the Uganda Cancer Institute’s adult Hematology/Oncology Fellowship Training Program. Dr. Gralow received the ASCO Humanitarian Award in 2018 for her work in empowering women cancer patients and survivors globally.

She is a recognized leader in breast cancer clinical research, and has conducted clinical trials in breast cancer prevention, treatment, and survivorship. Dr. Gralow served in leadership roles for the SWOG Cancer Research Network funded by the National Cancer Institute (NCI), including as Vice Chair of the Breast Cancer Committee and Executive Officer of Breast and Lung Cancer.

Before joining ASCO full-time, Dr. Gralow served the Society in a variety of volunteer and leadership roles, including chairing the ASCO Academic Global Oncology Task Force, co-chairing the ASCO Resource Stratified Guideline Advisory Group, and serving on the editorial board of the European Society of Medical Oncology (ESMO)/ASCO Global Curriculum in Medical Oncology.

She also has been involved with numerous other nonprofit organizations, including Team Survivor Northwest, an exercise and fitness program for woman cancer survivors which she co-founded in 1995 and serves as Team Physician; a medical advisory committee member for Cierra Sisters African American Support Group; an advisory board member of Global Focus on Cancer; and a Board member of Peace Island Medical Center, a rural access hospital in Washington State.

Dr. Gralow received her bachelor’s degree from Stanford University and her medical degree from the University of Southern California School of Medicine. She trained in internal medicine at Brigham and Women's Hospital at Harvard Medical School and completed a medical oncology fellowship at University of Washington/Fred Hutchinson Cancer Research Center in Seattle.

Expertise:
Request Interview
Robert Dreicer, MD, MS, MACP, FASCO
x

Robert Dreicer, MD, MS, MACP, FASCO is the Associate Director for Clinical Research and the Deputy Director of the University of Virginia Cancer Center. He serves as Section Head of Medical Oncology and Co-Director of the Paul Mellon Urologic Institute. He is a Professor of Medicine and Urology at the University of Virginia School of Medicine. He previously served as Chair of the Department of Solid Tumor Oncology at the Cleveland Clinic and Deputy Associate Director for Clinical Research for the Case Comprehensive Cancer Center. Dr. Dreicer is board certified in internal medicine and medical oncology. His areas of specialization are the management of genitourinary malignancies and the design and conduct of clinical trials in urologic oncology. Dr. Dreicer received his BS degree at Colorado State University and his MS degree at the University of Texas Graduate School of Biomedical Sciences in Houston, TX. He received his MD from the University of Texas Medical School at Houston. He completed an internal medicine residency at Indiana University in Indianapolis, followed by a medical oncology fellowship at the University of Wisconsin Carbone Clinical Cancer Center in Madison, Wisconsin. Dr. Dreicer has published widely in genitourinary oncology, and served as principle investigator of a large number of studies in genitourinary neoplasms. From 2012-18 he served as Co-Chair of the NCI GU Steering Committee. He is a member of the editorial board of New England Journal of Medicine’s Journal Watch Hematology/Oncology, as well as Lancet Oncology’s International Advisory Board. In October of 2016 he was awarded Mastership in the American College of Physicians.

Expertise:
Request Interview
Erica L. Mayer, MD, MPH
x

Erica L. Mayer, MD, MPH, is a Senior Physician and a breast cancer medical oncologist at the Susan F. Smith Center for Women’s Cancers/Dana-Farber Cancer Institute, as well as an Assistant Professor in Medicine at Harvard Medical School.

Dr. Mayer received her medical degree from Harvard Medical School in 2000. She completed a residency in Internal Medicine at Brigham and Women's Hospital, a chief residency in Internal Medicine at Faulkner Hospital, and a fellowship in Hematology/Oncology at Dana-Farber Cancer Institute/Partners CancerCare. She obtained a Master's in Public Health from the Harvard School of Public Health.

Dr. Mayer’s research focuses on the role of novel therapies in the treatment of advanced breast cancer. She has been published in numerous peer-reviewed publications including Nature, Journal of Biological Chemistry, Clinical Breast Cancer, Journal of Clinical Oncology, American Journal of Surgery, Annals of Oncology, and Clinical Cancer Research. She is the Associate Director of the Dana-Farber Partners CancerCare Hematology/Oncology Fellowship Program, and Co-Chair of the Dana-Farber Cancer Institute Clinical Faculty Council. Dr. Mayer is an active member of ASCO, ALLIANCE, as well as the Translational Breast Cancer Research Consortium. She is a graduate of the ASCO Leadership Development Program, has chaired the ASCO Cancer Education Committee Breast Track, and is a member of the ASCO Cancer Communications Committee.

Expertise:
Breast Cancer, Cancer Survivorship/Patient Care, Cardio-Oncology
Request Interview
Olatoyosi Odenike, MD
x

Olatoyosi Odenike, MD, is currently an Associate Professor of Hematology/Oncology in the Department of Medicine at the University of Chicago. She earned her medical degree from the University of Ibadan in Nigeria and completed her residency at the University of Illinois at Chicago, and fellowship in Hematology/Oncology at the University of Chicago.

An expert in the care of adults with leukemia, chronic myeloproliferative diseases and myelodysplastic syndromes, Dr. Odenike serves on the editorial board for the Blood Cancer Journal and Frontiers in Hematology-Oncology and as a reviewer for several medical journals. Additionally, she is a member of the Alliance Leukemia Committee, the International Working Group for Myelofibrosis Research and Treatment, the Molecular and Cellular Hematology NIH Study Section and currently serves on ASCO’s Grants Selection and Cancer Communications Committees.

Dr. Odenike has been listed in both Best Doctors of America and Marquis Who’s Who and is a  recipient of the ASCO Career Development Award. The overall goal of her research is to improve treatment options for patients with myeloid neoplasms. She has published a number of original articles and has served as the principal investigator in several clinical trials. Additionally, Dr. Odenike frequently speaks around the country on advances in leukemia and myeloproliferative neoplasms.

Expertise:
Request Interview
Jyoti D. Patel, FASCO, MD
x

Jyoti D. Patel, MD, is Associate Professor of Medicine, Division of Hematology/Oncology at Northwestern University Feinberg School of Medicine and leader of the Aerodigestive Malignancy Group of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University. Her clinical and research interests include lung cancer chemotherapy and lung cancer in women.

Expertise:
Request Interview